跳至主要内容
临床试验/NCT00097578
NCT00097578已完成不适用

An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Adenocarcinoma

Genentech, Inc.1 个研究点 分布在 1 个国家目标入组 1,953 人开始时间: 2004年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,953
试验地点
1

研究概览

简要总结

This is an observational study designed to follow patients with metastatic or locally advanced and unresectable colorectal cancer who are receiving Avastin in combination with chemotherapy and whose cancer has been either previously untreated or treated <=4 months prior to enrollment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Signed Informed Consent and Authorization document
  • Metastatic, or locally advanced and unresectable, adenocarcinoma of the colon or rectum
  • Receiving Avastin as a component of first-line chemotherapy
  • First-line chemotherapy plus Avastin initiated <=4 months prior to enrollment in the study

排除标准

  • Patients who have contraindications for treatment with Avastin (see the Avastin Package Insert) or who would incur excessive risks with Avastin treatment are ineligible for this study.

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验